Please assess the completion status of the following clinical trial:

Trial Title: Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Positive acid-fast bacillus (AFB) smear within 14 days prior to randomization~* Cluster of Differentiation 4 greater than 200 if HIV positive~* Ability to sign consent~* Bilateral, cavitary pulmonary TB~Exclusion Criteria:~* Multidrug-resistant (MDR) TB~* Extrapulmonary TB~* HIV positive with opportunistic infection within 30 days of study entry~* Cancer~* Asthma~* Pregnant or lactating women~* Chronic heart disease~* Chronic liver disease~* Chronic renal disease~* Seizure disorder~* Bleeding or clotting disorder~* Diabetes mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Standard Treatment (Type: PLACEBO_COMPARATOR): Isoniazid, Rifampin, Pyrazinamide Anti-Tuberculous Therapy
- Aerosol Interferon-gamma (Type: EXPERIMENTAL): Aerosol Interferon-Gamma plus Isoniazid, Rifampin, and Pyrazinamide
- Subcutaneous Interferon-Gamma (Type: EXPERIMENTAL): Subcutaneous Interferon-Gamma plus Isoniazid, Rifampin, and Pyrazinamide

Based on this trial design, predict the completion outcome and termination type (if applicable).